Berberine Drug Interactions: Which Medications Should Not Be Combined With Berberine

Berberine is a plant alkaloid that inhibits three families of liver enzymes responsible for metabolizing roughly 60 to 70 percent of all prescription drugs on the market. It also blocks P-glycoprotein, a transport protein that controls how much of an oral drug actually gets absorbed from your gut.

Most supplement-drug interactions are theoretical: extrapolated from test-tube studies that may or may not predict what happens in a human body. Berberine is different. It has a controlled pharmacokinetic study in actual patients showing a 34.5% increase in cyclosporine exposure. That is not a theoretical concern. That is a measured, clinically significant change in the blood level of a drug where being 30% over target can cause kidney failure.

This article covers which medications interact with berberine, through what mechanism, at what level of evidence, and what to do about it. The framework draws heavily on a 2026 narrative review published in Pharmaceuticals that mapped berberine's interaction potential across four mechanistic axes (Dumitru et al., 2026).

Why Berberine Causes So Many Interactions

A reasonable question: if berberine has terrible oral bioavailability, 0.68% in animal models, low nanogram-per-milliliter plasma concentrations in humans, how can it interfere with other drugs?

The answer is location. Berberine does not need to reach high blood levels to cause interactions. After you swallow a berberine capsule, it reaches high concentrations in the intestinal lumen and in enterocytes: the cells lining the small intestine where oral drugs are absorbed and undergo their first round of metabolism. It also concentrates in the liver during first-pass processing.

This matters because most oral drugs pass through the same intestinal cells and the same hepatic enzymes on their way into systemic circulation. Berberine is already sitting in those cells, inhibiting the machinery, when the other drug arrives.

The interaction happens at the point of absorption, before the other drug even reaches your bloodstream.

Axis 1: CYP Enzyme Inhibition

In vitro studies using human liver microsomes have shown that berberine and related goldenseal alkaloids inhibit CYP2D6, CYP2C9, and CYP3A4 activity (McDonald et al., 2020).

CYP3A4 alone is responsible for metabolizing approximately 50% of all marketed drugs. CYP2D6 handles another 20-25%, including most antidepressants and many cardiac medications. CYP2C9 metabolizes warfarin, several NSAIDs, and some oral hypoglycemics.

The CYP2D6 inhibition deserves special attention. It operates through a metabolite-intermediate complex, a mechanism that is quasi-irreversible. The enzyme does not simply slow down while berberine is present and resume normal activity when berberine clears. Instead, berberine's metabolite forms a stable complex with the enzyme that persists until the body synthesizes entirely new CYP2D6 protein. This process takes days to weeks. Stopping berberine does not immediately restore CYP2D6 activity.

This has practical consequences for drugs like codeine (which requires CYP2D6 to convert it to its active form, morphine) and tamoxifen (which requires CYP2D6 to convert it to its active metabolite, endoxifen). Berberine could reduce the effectiveness of these prodrugs even after you stop taking it.

Axis 2: P-glycoprotein Inhibition

P-glycoprotein (P-gp) is a pump embedded in the cell membranes of intestinal cells, liver cells, and kidney tubule cells. Its job is to push drugs back out: limiting absorption in the gut, promoting excretion in the liver and kidneys. It is a built-in defense mechanism against excessive drug exposure.

Berberine inhibits this pump (Pan et al., 2002). The practical result: more of the co-administered drug gets absorbed from the gut, less gets pumped back out by the liver, and less gets excreted by the kidneys. All three effects push in the same direction, higher blood levels of the other drug.

For medications with wide therapeutic windows: drugs where doubling the blood level might cause mild side effects but nothing dangerous, this is a manageable issue. For drugs with narrow therapeutic windows, cyclosporine, digoxin, warfarin, the same mechanism can push blood levels from therapeutic to toxic.

Axis 3: Pharmacodynamic Additivity

Some berberine interactions have nothing to do with enzyme inhibition. They are purely additive: berberine has its own pharmacological effects that stack on top of the same effects from medications.

Berberine lowers blood sugar. If you take it with metformin, you get more blood sugar lowering. That may be desirable (a 2025 combination study showed superior glycemic control) or it may cause hypoglycemia. The difference is monitoring and medical supervision.

Berberine lowers blood pressure modestly. Combined with antihypertensive medication, the result can be symptomatic hypotension.

Berberine has shown QT-prolonging potential in preclinical models. Combined with other QT-prolonging drugs, the theoretical risk is additive QT prolongation: which can trigger fatal cardiac arrhythmias.

Axis 4: Microbiome Effects (Candidate Axis)

Berberine significantly alters gut microbiome composition, this is one of its proposed mechanisms for metabolic benefits. But gut bacteria also metabolize certain drugs before they are absorbed. Changes to the microbiome could, in theory, alter how those drugs are processed.

The 2026 Dumitru review classifies this as a candidate axis rather than a demonstrated one. The science is plausible but the human interaction data is not yet available. Worth watching. Not yet worth worrying about clinically.

Quick-Reference Risk Matrix

The Cyclosporine Study: Grade A Evidence

This is the most important piece of evidence in berberine's entire interaction profile, and it deserves detailed examination because it demonstrates what berberine can do to a narrow-therapeutic-index drug in actual patients.

Wu et al. (2005) conducted a randomized controlled trial in renal transplant recipients at a Chinese hospital (Wu et al., 2005). The study had two components:

The clinical trial (n=104): 52 patients received cyclosporine plus berberine 0.2 g three times daily for three months. 52 controls received cyclosporine alone. In the berberine group, cyclosporine trough concentrations rose by 88.9% from baseline. But the control group also rose 64.5% from baseline (a natural drift in transplant patients). The net between-group difference at study end was 29.3% for trough concentration.

The pharmacokinetic substudy (n=6): Six patients received cyclosporine 3 mg/kg twice daily, with and without berberine 0.2 g three times daily for 12 days. Results:

• Cyclosporine AUC increased by 34.5%
• Apparent oral clearance decreased by 40.4%
• Time to peak concentration increased by 1.7 hours
• Half-life increased by 2.7 hours
• Minimum blood concentration increased by 88.3%
• Peak-to-trough fluctuation decreased by 50%

No significant changes in liver or kidney function were observed during the study, but the study ran only three months with dose-adjusted cyclosporine. The concern is what happens when a transplant patient adds berberine without telling their transplant team and without adjusting their cyclosporine dose. A 34% increase in cyclosporine AUC, unmonitored, can cause nephrotoxicity, neurotoxicity, and other serious adverse effects.

The Dumitru 2026 review classified this as Grade A evidence: the only Grade A interaction in berberine's profile.

High-Risk Interactions: Do Not Combine Without Physician Oversight

Cyclosporine and Tacrolimus (Immunosuppressants)

The cyclosporine data is summarized above. Tacrolimus shares the same metabolic pathway (CYP3A4 substrate, P-gp substrate) and the same narrow therapeutic window. No controlled PK study exists for berberine-tacrolimus, but the mechanistic basis is identical.

Transplant recipients should not take berberine. The risk-benefit calculation is heavily one-sided: berberine's metabolic benefits do not justify the possibility of subtherapeutic or supratherapeutic immunosuppressant levels in someone whose organ depends on staying within a narrow drug concentration range.

Warfarin

Warfarin has one of the narrowest therapeutic indices of any commonly prescribed drug. Its anticoagulant effect is monitored through INR testing, a number that must stay within a defined range to prevent both clots and bleeding.

S-warfarin (the more potent enantiomer) is metabolized by CYP2C9. R-warfarin is metabolized by CYP3A4. Berberine inhibits both enzymes. The predicted result is higher warfarin blood levels and elevated INR, increased bleeding risk.

Clinical reports have documented INR changes in warfarin patients who added berberine. If the combination cannot be avoided, INR must be monitored weekly for the first month and biweekly thereafter until a new stable baseline is established. But avoidance is the safer approach.

Direct Oral Anticoagulants (DOACs)

Apixaban is a CYP3A4 substrate and P-gp substrate. Rivaroxaban is similar. Dabigatran is primarily a P-gp substrate. Edoxaban is also a P-gp substrate.

Berberine's inhibition of both CYP3A4 and P-gp could increase DOAC blood levels and bleeding risk. No controlled pharmacokinetic data exists for any berberine-DOAC pair. The mechanistic rationale is strong enough that most pharmacists would flag the combination, and the consequence of the interaction (bleeding) is serious enough that caution is warranted.

Digoxin

Digoxin is a P-gp substrate with an extremely narrow therapeutic window. The difference between a therapeutic digoxin level and a toxic one is small: and digoxin toxicity can cause fatal cardiac arrhythmias.

Berberine's P-gp inhibition can increase digoxin absorption and reduce its renal clearance. Digoxin levels should be monitored closely if the combination is used, with testing at baseline, one week, and one month after starting berberine.

Moderate-Risk Interactions: Use With Monitoring

Diabetes Medications

Berberine lowers blood glucose through AMPK activation, alpha-glucosidase inhibition, microbiome modulation, and improved insulin sensitivity. Combined with diabetes medications, the effects are additive.

Metformin: The most commonly asked-about combination. Both activate AMPK through partially different upstream pathways. A 2025 study (Jie et al.) found the combination achieved a 96% effective rate versus 82% for metformin alone, genuinely promising. But additive glucose-lowering means additive hypoglycemia risk. A 2025 study in Scientific Reports confirmed that metformin and berberine synergistically act through the AMPK-SREBP1-FASN pathway (Li et al., 2025). Blood glucose monitoring in the first 2-4 weeks is not optional. Spacing doses, berberine with one meal, metformin with another, may reduce peak additive effect.

Sulfonylureas (glipizide, glyburide): These drugs force the pancreas to release more insulin regardless of glucose level. Adding berberine's glucose-lowering effect on top creates meaningful hypoglycemia risk, especially in older adults.

Insulin: Same additive risk. Insulin dose adjustment may be needed when adding or removing berberine.

GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide): Additive effect on both blood sugar and GI side effects. The "nature's Ozempic" marketing of berberine makes this combination increasingly common: and increasingly in need of clinical supervision. See GLP-1 side effects for the GI effects these drugs already cause.

Statins

Not all statins carry the same risk:

Higher risk: Simvastatin and lovastatin are heavily CYP3A4-dependent. Berberine can increase their blood levels, raising the risk of myopathy and, in rare cases, rhabdomyolysis (skeletal muscle breakdown). An in vivo study confirmed significant pharmacokinetic changes when berberine was co-administered with lovastatin, with altered AUC and Cmax values (Chen et al., 2018).

Atorvastatin is also a CYP3A4 substrate, though it has a wider therapeutic margin than simvastatin.

Lower risk: Rosuvastatin and pravastatin are primarily renally cleared, with minimal CYP3A4 involvement. If you take a statin and want to add berberine, discuss switching to one of these with your physician.

Ironically, berberine and statins are often combined intentionally for their additive cholesterol-lowering effects. This can work, but the statin choice matters, and the combination should be physician-supervised.

Blood Pressure Medications

Berberine has mild antihypertensive effects. Combined with calcium channel blockers, ACE inhibitors, ARBs, or beta-blockers, the additive effect can produce symptomatic hypotension, dizziness, lightheadedness, fainting, especially when standing up quickly.

This interaction is more annoying than dangerous in most cases, but in elderly patients or those on aggressive blood pressure regimens, it can cause falls: which are themselves a significant medical risk.

Benzodiazepines

Midazolam and other benzodiazepines metabolized by CYP3A4 may accumulate with berberine co-administration. The result is intensified sedation, impaired coordination, and (in the worst case) respiratory depression. This combination is particularly concerning in elderly patients, who metabolize benzodiazepines more slowly to begin with.

QT-Prolonging Medications

Berberine has demonstrated QT-prolonging potential in preclinical models. Drugs in this category include certain antiarrhythmics (amiodarone, sotalol), antipsychotics (haloperidol, ziprasidone), fluoroquinolone antibiotics (moxifloxacin, levofloxacin), and some antiemetics (ondansetron).

The combined QT risk is theoretical but carries high consequences, torsades de pointes, a potentially fatal arrhythmia. If you take any QT-prolonging medication, disclose your berberine use.

Lower-Risk Interactions

Thyroid Medications

Levothyroxine absorption can theoretically be affected by berberine's modulation of intestinal transporters. Separate doses by at least two hours as a precaution. Continue routine thyroid function monitoring.

Antibiotics

Short courses of macrolide antibiotics (azithromycin, clarithromycin) may interact transiently. Inform your prescriber.

Acetaminophen

Chronic acetaminophen use combined with CYP enzyme modulation can alter the production of NAPQI, acetaminophen's hepatotoxic metabolite. Occasional use is unlikely to be clinically significant. Daily or near-daily acetaminophen use alongside berberine warrants discussion with a pharmacist. See our berberine liver safety article for more context on this pathway.

The Publication Bias Problem

A critical caveat from the 2026 Dumitru review that most berberine interaction articles omit: the published evidence almost certainly overstates berberine's interaction frequency and magnitude.

Studies that find an interaction get published. Studies that look for an interaction and find nothing rarely make it to print. Negative pharmacokinetic results for supplement-drug pairs are especially unpublishable: no journal gets excited about "we combined these two things and nothing happened."

The result is a literature that disproportionately represents positive findings. The cyclosporine interaction is real and well-documented. Many of the other predicted interactions may be smaller in practice than the mechanistic evidence suggests. This does not mean they should be ignored, it means they should be managed through monitoring and physician awareness rather than panic.

What You Should Actually Do

The pharmacist at your corner pharmacy is the most underused safety resource in healthcare. Here is how to use them:

Before starting berberine: Bring your complete medication list (prescription drugs, OTC medications, and all other supplements) to your pharmacist. Ask them to screen for interactions. This takes five minutes and costs nothing. Many pharmacy systems have drug interaction databases that include major supplements.

When seeing any doctor: Disclose berberine use unprompted. Do not wait to be asked about supplements. Many physicians do not routinely ask, and many patients do not consider supplements to be "medications." This communication gap is where interactions cause harm.

If you are on a narrow-therapeutic-index drug: Cyclosporine, tacrolimus, warfarin, digoxin, lithium, theophylline, phenytoin: if you take any of these, discuss berberine with your prescribing physician before starting. These drugs require therapeutic drug monitoring specifically because small changes in blood levels can cause serious harm.

Monitor what is monitorable. If you take diabetes medications, check your blood sugar more frequently for the first month. If you take antihypertensives, monitor your blood pressure. If you take warfarin, ensure your INR schedule accounts for the new variable.

Time your doses. Taking berberine and interacting medications at different times does not eliminate the interaction (CYP and P-gp inhibition persists between doses) but it may reduce peak concentration overlap for some drug pairs. Morning berberine, evening medication (or vice versa) is a reasonable spacing strategy. It is harm reduction, not harm elimination.

Frequently Asked Questions

Can I take berberine with my blood pressure medication?

Berberine mildly lowers blood pressure, so combining it with ACE inhibitors, ARBs, calcium channel blockers, or diuretics can cause additive hypotension, especially in older adults. This is a pharmacodynamic interaction, not a metabolism issue. Monitor your blood pressure more closely for the first 2 weeks and watch for dizziness, lightheadedness, and fatigue.

Berberine has a mild blood-pressure-lowering effect of its own. Combining it with ACE inhibitors, ARBs, calcium channel blockers, or diuretics may produce additive hypotension, especially in older adults or people who already run low-normal blood pressure. This is a pharmacodynamic interaction (two substances pushing the same direction), not a drug metabolism issue. If you take antihypertensives, monitor your blood pressure more frequently after starting berberine, particularly during the first 2 weeks. Symptoms to watch for: dizziness on standing, lightheadedness, and fatigue. Your physician may want to adjust your medication dose rather than eliminate berberine, since the combined effect on blood pressure can be clinically useful when monitored.

Is berberine safe with metformin?

The combination is not contraindicated but needs closer glucose monitoring. Both berberine and metformin activate AMPK and lower blood sugar, so the main concern is additive hypoglycemia. Berberine also affects OCT1 and OCT2 transporters involved in metformin handling. If you take both, monitor glucose closely, eat regular meals, and inform your prescriber.

This is one of the most common drug interaction questions for berberine. Both compounds activate AMPK and lower blood glucose: so the primary concern is additive hypoglycemia, not a CYP-mediated interaction. Berberine also affects OCT1 and OCT2 transporters, which are involved in metformin uptake by hepatocytes and renal clearance. A 2025 in vitro study suggested they may work synergistically through the AMPK-SREBP1-FASN pathway, but clinical interaction studies in humans are lacking. If you take both, monitor blood glucose closely, eat regular meals, and inform your prescriber. The combination is not contraindicated, but it does require more vigilant glucose monitoring than either substance alone.

Does berberine interact with birth control pills?

Possibly, though it is unquantified. Most oral contraceptives are metabolized by CYP3A4, which berberine inhibits, potentially raising rather than lowering hormone levels. No study has directly tested berberine's effect on contraceptive efficacy. If reliable contraception is critical, inform your gynecologist and consider a backup method during the first cycle after starting berberine.

Most oral contraceptives are metabolized by CYP3A4, which berberine inhibits. In theory, CYP3A4 inhibition could alter hormone metabolism, but the direction of effect is not straightforward. Inhibiting CYP3A4 would reduce estrogen breakdown, potentially increasing circulating hormone levels rather than decreasing them. No published study has specifically tested berberine's effect on oral contraceptive efficacy. The theoretical concern is real but unquantified. If reliable contraception is critical, consider informing your gynecologist about berberine use and using a backup method during the first cycle after starting berberine.

How long after stopping a medication should I wait before starting berberine?

A 2-week washout in either direction provides a conservative margin. Berberine's CYP2D6 inhibition is quasi-irreversible, so its effect outlasts its own plasma clearance, and enzyme activity takes several days to recover after stopping. For CYP3A4 interactions, recovery may be faster since berberine both inhibits and induces that enzyme depending on dose.

This depends on the medication's half-life, and berberine's CYP inhibition characteristics. Berberine's CYP2D6 inhibition appears to be quasi-irreversible (it forms a metabolite-intermediate complex that does not release quickly), meaning its inhibitory effect outlasts its own plasma clearance. After stopping berberine, CYP2D6 activity may take several days to recover because the body needs to synthesize new enzyme protein. A 2-week washout in either direction: between stopping a CYP2D6-dependent medication and starting berberine, or vice versa, provides a conservative margin. For CYP3A4 interactions, the recovery may be faster since berberine both inhibits and induces this enzyme depending on dose and duration.

Should I tell my pharmacist about berberine?

Yes, and it is arguably more important than telling your doctor. Pharmacists run interaction databases when filling prescriptions, but only against substances they know you take. Since berberine is sold as a supplement, it is not in your profile by default. Adding it manually screens every future prescription against berberine's CYP and P-glycoprotein interactions.

Yes, and this is arguably more important than telling your doctor. Pharmacists run drug interaction databases when filling prescriptions, but these databases only flag interactions with substances the pharmacist knows you are taking. Berberine is not typically listed in a patient's medication profile because it is sold as a supplement, not a prescription. Adding it manually ensures that every future prescription is screened against berberine's CYP2D6, CYP3A4, CYP2C9, and P-glycoprotein interactions. This 30-second conversation at the pharmacy counter provides ongoing automated protection that a single doctor's visit does not.

Who should avoid combining berberine with their medications?

Berberine interacts with many drug classes, so several groups should not add it without medical supervision. Because berberine inhibits the CYP enzymes and transporters that clear most medications, people on the drug classes below should involve their prescriber and pharmacist before starting.

Diabetes medication users. Berberine lowers blood sugar through the same AMPK pathway as metformin. Combined with metformin, sulfonylureas, or insulin, it raises hypoglycemia risk and requires closer glucose monitoring.

People on blood pressure medication. Berberine has a mild blood-pressure-lowering effect. Stacked with ACE inhibitors, ARBs, calcium channel blockers, or diuretics, it can cause additive hypotension, especially in older adults.

Transplant recipients on immunosuppressants. Berberine sharply raises cyclosporine blood levels, as a renal-transplant RCT demonstrated. Any transplant patient must involve their transplant team before considering berberine.

Anyone on narrow-therapeutic-index drugs. Warfarin, certain antiarrhythmics, and other drugs with a narrow safety margin are especially vulnerable to berberine's CYP inhibition. Even small changes in blood levels can matter, so medical oversight is essential.

The Bottom Line

Berberine inhibits CYP3A4, CYP2D6, CYP2C9, and P-glycoprotein. That combination gives it one of the broadest drug interaction profiles of any supplement you can buy without a prescription.

The highest-risk combinations (cyclosporine, tacrolimus, warfarin, digoxin) involve medications where a 30% change in blood levels can mean the difference between therapy and toxicity. For these, berberine should be avoided entirely unless your prescribing physician explicitly approves and monitors the combination.

For moderate-risk combinations, statins, diabetes medications, blood pressure drugs, benzodiazepines, informed use with physician oversight is possible. The key word is "informed." Most of the real-world harm from berberine interactions happens not because the interaction is unmanageable, but because nobody knew the patient was taking berberine.

That five-minute conversation with your pharmacist is the most important safety measure this article can recommend.

---

Written by Tao Wu. This article is based on peer-reviewed pharmacokinetic research and the 2026 four-axis interaction framework. YourHealthier sells berberine supplements. See our editorial policy for how we research and write.

Last updated: September 2026

Because the interactions described above can be clinically significant, the safest approach is always to involve your prescriber and pharmacist before adding berberine to any medication regimen. The information here is educational and has not been evaluated by the FDA; it is not intended to diagnose, treat, cure, or prevent any disease.

---

References

Dumitru CN, Marcu T, Dumitru AO, et al. Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification, A Narrative Review. *Pharmaceuticals*. 2026;19(8):1313. PubMed: 42653808

Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. *European Journal of Clinical Pharmacology*. 2005;61(8):567-572. PubMed: 16133554

Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients. *European Journal of Clinical Pharmacology*. 2005;61(8):567-572.

Pan GY, Wang GJ, Liu XD, Fawcett JP, Xie YY. The involvement of P-glycoprotein in berberine absorption. *Pharmacology & Toxicology*. 2002;91(4):193-197. PubMed: 12530470

McDonald MG, Tian DD, Thummel KE, et al. Modulation of Major Human Liver Microsomal Cytochromes P450 by Component Alkaloids of Goldenseal. *Drug Metabolism and Disposition*. 2020;48(10):1018-1027. PubMed: 32591416

Chen W, Miao YQ, Fan DJ, et al. In Vivo and in Vitro Study on Drug-Drug Interaction of Lovastatin and Berberine from Pharmacokinetic and HepG2 Cell Metabolism Studies. *Molecules*. 2018;23(12):3042. PMC: 6272956

Li N, Chen QW, Gong XL, et al. Metformin and berberine synergistically improve NAFLD via the AMPK-SREBP1-FASN signaling pathway. *Scientific Reports*. 2025;15(1):29400. PubMed: 40790070

Dong H, Wang N, Zhao L, Lu F. Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis. *Evidence-Based Complementary and Alternative Medicine*. 2012;2012:591654. PubMed: 23118793

Yin J, Xing H, Ye J. Efficacy of berberine in patients with type 2 diabetes mellitus. *Metabolism*. 2008;57(5):712-717. PubMed: 18442638

GoodRx Health. 8 Berberine Drug Interactions You Should Know About. Updated August 2026. GoodRx